chronic rhinosinusitis News
-
Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that four abstracts highlighting LYR-210 results in chronic rhinosinusitis and the XTreo™ platform have been ...
-
Lyra Therapeutics To Present Lantern Phase 2 Study Results For Lyr 210 In Oral Presentation At Cosm 2021 Virtual
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that the company will present Phase 2 results from the LANTERN study for LYR-210, the company’s lead product candidate ...
-
AxioSonic will be presenting at AAO-HNSF Annual Meeting & OTO Expo
Vivek Ramakrishnan will be presenting at AAO-HNSF on a poster titled: “Treatment of Rhinosinusitis with Topical Ultrasound”. The poster summarizes data from a clinical study supporting the use of therapeutic ultrasound for treatment in facial pain in patients diagnosed with chronic rhinosinusitis. The American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) ...
-
Understanding the Difference between COVID-19 Symptoms and Sinus Disease World Sinus Health Awareness Day 2021
The American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), in partnership with Intersect ENT, Inc., launched a public education campaign that provides clinically-developed information by experts in the field aimed at helping people better understand their nasal and sinus symptoms. World Sinus Health Awareness Day, with its inaugural celebration on September 29, has an ...
-
Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology
Company to Initiate Phase 3 ENLIGHTEN Program around YE’21 Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that the positive results of the Company’s Phase ...
-
Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy
Outcomes supported advancing into clinical development for LYRA’s first indication, Chronic Rhinosinusitis, with lead product candidate, LYR-210, currently poised to enter Phase 3 studies Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, ...
-
Lyra Therapeutics to Highlight LYR-210 and LYR-220 Clinical Programs at Virtual Event with Leading Clinical CRS Experts
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues will host a virtual event with leading chronic rhinosinusitis (CRS) experts to highlight the Company's LYR-210 and LYR-220 clinical ...
-
Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues will host Chronic Rhinosinusitis (CRS) Key Opinion Leader Event on Tuesday, August 31, 2021 from 3:00 p.m. - 4:30 p.m. ET. Robert Kern, ...
-
Intersect ENT Receives CE Mark Approval for PROPEL Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced it has received CE Mark approval for the company’s PROPEL Contour (mometasone furoate) sinus implant enabling sales and distribution in the European Union. The Contour CE approval expands the portfolio of PROPEL products ...
-
First Implants of PROPEL Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken Wiesbaden in Germany was the first hospital outside the United States to offer the Company’s PROPEL® Contour (mometasone furoate) sinus implant following functional endoscopic ...
-
Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D., Lyra's President and Chief Executive Officer, will present in a virtual format at three ...
-
TISSIUM Awarded 2.2M€ from i-Nov Competition to Address Chronic Rhinosinusitis
TISSIUM, a privately-owned life science company developing fullysynthetic, biomorphic programmable polymers, announced today it has been awarded 2.2M€ in financing that will accelerate its development of a drug-eluting tissue adhesive to address the unmet needs of Chronic Rhinosinusitis (CRS) patients. The funding comes from the Investments for the Future program (Programme ...
By TISSIUM
-
Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D., Lyra’s President and Chief Executive Officer, will present in a virtual format at the ...
-
Lyra Therapeutics Provides Corporate Update and Anticipated Milestones for 2021
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today provided a corporate update and anticipated milestones for 2021. Corporate Update & Anticipated Milestones for 2021 LYR-210: ...
-
Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Society
LYR-210 pharmacokinetics indicate a constant and steady daily dose of Mometasone Furoate is delivered to patients LANTERN study manuscript wins ARS Annual Meeting 2021 Clinical Science Maurice Cottle Award Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of ...
-
FDA Accepts Dupixent (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) 300 mg weekly to treat adult and pediatric patients aged 12 years and older with eosinophilic esophagitis (EoE), a chronic and progressive type 2 inflammatory ...
-
Lyra Therapeutics Announces Initiation Of Lyr-210 Pivotal Phase 3 Enlighten Program In Surgically Naïve Chronic Rhinosinusitis Patients
LYR-210 and LYR-220 are designed to complement each other in addressing the broad spectrum of CRS patients treated by ENT Physicians Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, ...
-
Medtronic to Acquire Intersect ENT
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has entered into a definitive agreement with Intersect ENT (NASDAQ: XENT), a global ear, nose, and throat (ENT) medical technology leader dedicated to transforming patient care, in which Medtronic will acquire all outstanding shares of Intersect ENT for $28.25 per share in an all-cash transaction implying ...
-
CMS Consolidates SINUVA Sinus Implant Coverage Under a Distinct Code, J7402, and Publishes an ASP Clarifying Payment and Easing Payer Coverage Adjudication
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that the Centers for Medicare and Medicaid Services (CMS) published an average selling price (ASP) for the Company’s SINUVA sinus implant, providing predictability, transparency, and confidence of reimbursement for ...
-
Lyra Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update. Key Fourth ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you